Brain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity

Cells. 2023 Mar 21;12(6):957. doi: 10.3390/cells12060957.

Abstract

Brain vascular health appears to be critical for preventing the development of amyotrophic lateral sclerosis (ALS) and slowing its progression. ALS patients often demonstrate cardiovascular risk factors and commonly suffer from cerebrovascular disease, with evidence of pathological alterations in their small cerebral blood vessels. Impaired vascular brain health has detrimental effects on motor neurons: vascular endothelial growth factor levels are lowered in ALS, which can compromise endothelial cell formation and the integrity of the blood-brain barrier. Increased turnover of neurovascular unit cells precedes their senescence, which, together with pericyte alterations, further fosters the failure of toxic metabolite removal. We here provide a comprehensive overview of the pathogenesis of impaired brain vascular health in ALS and how novel magnetic resonance imaging techniques can aid its detection. In particular, we discuss vascular patterns of blood supply to the motor cortex with the number of branches from the anterior and middle cerebral arteries acting as a novel marker of resistance and resilience against downstream effects of vascular risk and events in ALS. We outline how certain interventions adapted to patient needs and capabilities have the potential to mechanistically target the brain microvasculature towards favorable motor cortex blood supply patterns. Through this strategy, we aim to guide novel approaches to ALS management and a better understanding of ALS pathophysiology.

Keywords: amyotrophic lateral sclerosis; exerkines; motor cortex; pericytes; vascular supply.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / metabolism
  • Blood-Brain Barrier / pathology
  • Humans
  • Motor Cortex* / metabolism
  • Motor Neurons / pathology
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Vascular Endothelial Growth Factor A

Grants and funding

This work was funded by the Deutsche Forschungsgemeinschaft (DFG) (MA 9235/3-1/SCHR 1418/5-1 (501214112), MA 9235/1-1 (446268581), CRC 1436 (B04, 425899996), and RTG 2413 (SynAGE, 362321501)), by the Medical Faculty of the Otto von Guericke University Magdeburg (scholarship to P.A.) and by the Deutsche Alzheimer Gesellschaft (DAG) e.V. (MD-DARS project). The computational PVS quantification was supported by The Galen and Hilary Weston Foundation under the Novel Biomarkers 2019 scheme (ref UB190097) administered by the Weston Brain Institute and the Row Fogo Charitable Trust (ref no. BRO-D.FID3668413).